WALTHAM, Mass., Sept.14 Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, following its launch and uptake, GlaxoSmithKline's angiogenesis inhibitor Votrient (formerly Armala) will garner sales of $640 million by 2018 and will take significant market share away from Pfizer's Sutent. In 2008, Sutent had accounted for 61 percent of sales in the angiogenesis inhibitor drug class.
The new Pharmacor report entitled Renal Cell Carcinoma finds that Votrient will overtake Sutent as the renal cell carcinoma market leader by 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. For the treatment of renal cell carcinoma, Votrient is expected to launch in the U.S. in 2010, in Europe in 2011 and in Japan in 2012. According to the report, the angiogenesis inhibitor drug class will continue to dominate this market over the next decade, capturing 87 percent of total sales in 2018.
The report also finds that Novartis's Afinitor and Pfizer's axitinib will surpass Bayer Healthcare/Onyx's Nexavar and Wyeth's Torisel by 2018 in the second- and third-line treatment settings. In 2008, Nexavar was the leading therapy in the second-line setting and Torisel was the leading therapy in the third-line setting for the treatment of renal cell carcinoma.
"Thought leaders we interviewed indicate that they are optimistic about several emerging therapies, most notably axitinib and Votrient," said Decision Resources Analyst Karen Pomeranz, M.Sc., Ph.D. "One expert called axitinib 'the most exciting' emerging agent in renal cell carcinoma in recent years and another thought leader said that Votrient's clinical efficacy is comparable to that of Sutent and that Votrient has a more favorable side-effect profile than Sutent."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 email@example.com firstname.lastname@example.org
SOURCE Decision Resources